2015
DOI: 10.1158/1538-7445.am2015-4395
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 4395: Strategy to overcome inherent TRAIL-based therapeutic limitations

Abstract: TNF-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent because of its selective ability to induce apoptosis in activated immune cells or cancer cells with minimal toxicity in normal cells. However, a short biological half-life and the development of inherent TRAIL resistance in a variety of cancer cells, including colorectal cancer cells (CRC), results in the poor performance of TRAIL as a chemotherapeutic agent. To overcome these limitation, we developed PEGylated TRAIL (PEG-TRAIL) to … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles